Grand Pharmaceutical Group Strengthens Strategic Investment in Telix

Grand Pharmaceutical Group Limited ( (HK:0512) ) has issued an update.

Grand Pharmaceutical Group Limited has announced the sale of approximately 45.2% of its shares in Telix Pharmaceuticals Limited, raising AU$143 million to fund clinical development plans. Despite the sale, the company remains committed to its partnership with Telix, retaining 6 million shares and collaborating on innovative cancer imaging and therapeutic products. The announcement highlights the success of Telix’s prostate cancer imaging agent, TLX591-CDx, which has achieved significant global sales and regulatory approvals, underscoring the potential for future growth and value creation in their joint endeavors.

More about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited is a company incorporated in Bermuda with a focus on the pharmaceutical industry. It specializes in the development and commercialization of imaging and therapeutic products, particularly in the areas of prostate, renal, and brain cancer. The company holds exclusive rights to Telix Pharmaceuticals’ portfolio in the Greater China market.

YTD Price Performance: 8.12%

Average Trading Volume: 3,282,049

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: HK$18.42B

For detailed information about 0512 stock, go to TipRanks’ Stock Analysis page.